Key result
DOAC use is linked to ~60% lower odds of LAA thrombus vs. warfarin.
Why the study?
The use of transesophageal echocardiography before electrophysiological procedures in anticoagulated patients with atrial fibrillation or flutter is variable, prompting evaluation of the incidence and predictors of left atrial appendage thrombus.
Does direct oral anticoagulant use reduce the presence of LAA thrombus on TEE compared to warfarin in patients with AF/AFl undergoing cardioversion or ablation?
Cohort (n=401)
No
Does direct oral anticoagulant use reduce the presence of LAA thrombus on TEE compared to warfarin in patients with AF/AFl undergoing cardioversion or ablation?
Despite preprocedural anticoagulation, a significant proportion of AF/AFl patients have LAA thrombi prior to electrophysiology procedures, particularly those with heart failure, prior stroke, or taking warfarin rather than DOACs.
Answers are grounded in this paper and cite their sources.
DOAC use was associated with lower LAA thrombus odds than warfarin; does not yet support changing periprocedural anticoagulation without randomized confirmation.
BACKGROUND: Cerebral thromboembolism is a potentially devastating complication of atrial fibrillation (AF) and atrial flutter (AFl). The use of transesophageal echocardiogram (TEE) before electrophysiological procedures in anticoagulated patients is variable. Our objective was to determine the incidence and identify predictors of intracardiac left atrial appendage (LAA) thrombus on TEE in patients with AF/AFl before electrical cardioversion or ablation. METHODS: We reviewed TEEs of 401 patients undergoing an electrical cardioversion, AF, or AFl ablation from April 2013 to September 2015 at the McGill University Health Center. Clinical and echocardiographic variables were collected at the time of the TEE and follow-up visits. Multivariate logistic regression was used to determine predictors of LAA thrombus. RESULTS: Of 401 patients, 11.2% had LAA thrombus on TEE. The majority (87%) of patients were anticoagulated for at least 3 weeks before the TEE. The incidence of LAA thrombus was 21% (23/110) in patients taking warfarin vs 6.4% (15/236) in patients taking direct oral anticoagulants. Multivariate analysis identified prior stroke (odds ratio [OR], 2.7; 95% confidence interval [CI], 1.1-6.9) and heart failure (OR, 2.2; 95% CI, 1.0-4.7) as predictors of thrombus, whereas direct oral anticoagulant use (OR, 0.4; 95% CI, 0.2-0.8) was associated with reduced odds of thrombus. CONCLUSIONS: LAA thrombus was identified in a significant proportion of patients undergoing TEE before cardioversion or ablation of AF/AFl despite preprocedural anticoagulation. Patients at increased risk of LAA thrombus (heart failure and prior stroke) may benefit from TEE before cardioversion, AF, or AFl ablation.
No takes yet. Share an insight, caveat, or question.
Rawahi et al. (2019) conducted a cohort in Atrial fibrillation and atrial flutter (n=401). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on Presence of left atrial appendage (LAA) thrombus on transesophageal echocardiography (OR 0.40, 95% CI 0.19-0.82, p=0.01). Direct oral anticoagulant use was associated with reduced odds of left atrial appendage thrombus compared to warfarin, while prior stroke and heart failure were independent predictors of thrombus.
Synapse has enriched 10 related papers. Consider them for comparative context: